HPCI News: Lower Prescription Drug Prices
To: Members and Selected Others
Health and Human Services Secretary Azar recently announced
actions to execute on his plan to lower prescription drug prices.
The three key initiatives below hold real promise to add value and
reduce cost.
FDA Announces a Biosimilar Action Plan
The FDA released a Biosimilar Action Plan outlining how to improve
efficiency and scientific and regulatory clarity for product
development, increase communications to expand use of biosimilar and
support market competition by reducing gaming
FDA
Actions to Improve Access to Over-the-Counter Drugs
The
FDA released draft guidance on two innovative approaches to increase
access to a broader selection of nonprescription drug products for
consumers, empowering them to self-treat common conditions and
potentially some chronic conditions.
Prescription
Drug Importation Workgroup Established
Requested that
FDA Commissioner Scott Gottlieb establish a working group to examine
how to safely import prescription drugs from other countries in the
event of a dramatic price increase for a drug produced by one
manufacturer and not protected by patents or exclusivities.
For more information please contact the HPCI office.
Paul M. Pietzsch, MPH
HPCI - IHBA Office
4430 Ashley Park Drive
West Des Moines, Iowa 50265
(515) 778-6300